<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:06:58 -0700</creation_date>
  <update_date>2013-01-15 19:06:58 -0700</update_date>
  <accession>HMDBP02643</accession>
  <secondary_accessions>
    <accession>8143</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>M-OR-1</synonym>
    <synonym>MOP</synonym>
    <synonym>MOR-1</synonym>
    <synonym>Mu opiate receptor</synonym>
    <synonym>Mu opioid receptor</synonym>
    <synonym>hMOP</synonym>
  </synonyms>
  <gene_name>OPRM1</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Receptor for beta-endorphin</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00464</accession>
      <name>Calcium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04999</accession>
      <name>Loperamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04995</accession>
      <name>Codeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14339</accession>
      <name>Tramadol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14440</accession>
      <name>Morphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14477</accession>
      <name>Methadone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14640</accession>
      <name>Oxycodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14647</accession>
      <name>Levallorphan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14749</accession>
      <name>Butorphanol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14785</accession>
      <name>Propoxyphene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14790</accession>
      <name>Pentazocine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14842</accession>
      <name>Naltrexone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14846</accession>
      <name>Sufentanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14940</accession>
      <name>Alfentanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14951</accession>
      <name>Fentanyl</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14982</accession>
      <name>Nalbuphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14992</accession>
      <name>Levorphanol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15036</accession>
      <name>Remifentanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15049</accession>
      <name>Anileridine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15091</accession>
      <name>Hydrocodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15213</accession>
      <name>Diphenoxylate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15314</accession>
      <name>Naloxone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15323</accession>
      <name>Oxymorphone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15340</accession>
      <name>Dezocine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15358</accession>
      <name>Levomethadyl Acetate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15502</accession>
      <name>Methadyl Acetate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15509</accession>
      <name>Ethylmorphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15631</accession>
      <name>Alvimopan</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>peptide receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>peptide receptor activity, g-protein coupled</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>opioid receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>mu-opioid receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:6</chromosome_location>
    <locus>6q24-q25</locus>
    <gene_sequence>&gt;1203 bp
ATGGACAGCAGCGCTGCCCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCA
AGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTTGTCCCACTTAGATGGCAAC
CTGTCCGACCCATGCGGTCCGAACCGCACCGACCTGGGCGGGAGAGACAGCCTGTGCCCT
CCGACCGGCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTCTACTCCATCGTG
TGCGTGGTGGGGCTCTTCGGAAACTTCCTGGTCATGTATGTGATTGTCAGATACACCAAG
ATGAAGACTGCCACCAACATCTACATTTTCAACCTTGCTCTGGCAGATGCCTTAGCCACC
AGTACCCTGCCCTTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTTGGAACCATC
CTTTGCAAGATAGTGATCTCCATAGATTACTATAACATGTTCACCAGCATATTCACCCTC
TGCACCATGAGTGTTGATCGATACATTGCAGTCTGCCACCCTGTCAAGGCCTTAGATTTC
CGTACTCCCCGAAATGCCAAAATTATCAATGTCTGCAACTGGATCCTCTCTTCAGCCATT
GGTCTTCCTGTAATGTTCATGGCTACAACAAAATACAGGCAAGGTTCCATAGATTGTACA
CTAACATTCTCTCATCCAACCTGGTACTGGGAAAACCTGCTGAAGATCTGTGTTTTCATC
TTCGCCTTCATTATGCCAGTGCTCATCATTACCGTGTGCTATGGACTGATGATCTTGCGC
CTCAAGAGTGTCCGCATGCTCTCTGGCTCCAAAGAAAAGGACAGGAATCTTCGAAGGATC
ACCAGGATGGTGCTGGTGGTGGTGGCTGTGTTCATCGTCTGCTGGACTCCCATTCACATT
TACGTCATCATTAAAGCCTTGGTTACAATCCCAGAAACTACGTTCCAGACTGTTTCTTGG
CACTTCTGCATTGCTCTAGGTTACACAAACAGCTGCCTCAACCCAGTCCTTTATGCATTT
CTGGATGAAAACTTCAAACGATGCTTCAGAGAGTTCTGTATCCCAACCTCTTCCAACATT
GAGCAACAAAACTCCACTCGAATTCGTCAGAACACTAGAGACCACCCCTCCACGGCCAAT
ACAGTGGATAGAACTAATCATCAGCTAGAAAATCTGGAAGCAGAAACTGCTCCGTTGCCC
TAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>400</residue_number>
    <molecular_weight>44778.9</molecular_weight>
    <theoretical_pi>8.29</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>67-96</region>
      <region>106-123</region>
      <region>146-165</region>
      <region>196-211</region>
      <region>237-259</region>
      <region>283-305</region>
      <region>314-330</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Mu-type opioid receptor
MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP</protein_sequence>
  </protein_properties>
  <genbank_protein_id>117940060</genbank_protein_id>
  <uniprot_id>P35372</uniprot_id>
  <uniprot_name>OPRM_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>NM_000914.3</genbank_gene_id>
  <genecard_id>OPRM1</genecard_id>
  <geneatlas_id>OPRM1</geneatlas_id>
  <hgnc_id>HGNC:8156</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR: Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett. 1994 Jan 31;338(2):217-22.</reference_text>
      <pubmed_id>7905839</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bare LA, Mansson E, Yang D: Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett. 1994 Nov 7;354(2):213-6.</reference_text>
      <pubmed_id>7957926</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mestek A, Hurley JH, Bye LS, Campbell AD, Chen Y, Tian M, Liu J, Schulman H, Yu L: The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J Neurosci. 1995 Mar;15(3 Pt 2):2396-406.</reference_text>
      <pubmed_id>7891175</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pan YX, Xu J, Mahurter L, Xu M, Gilbert AK, Pasternak GW: Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun. 2003 Feb 21;301(4):1057-61.</reference_text>
      <pubmed_id>12589820</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW: Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience. 2005;133(1):209-20.</reference_text>
      <pubmed_id>15893644</pubmed_id>
    </reference>
    <reference>
      <reference_text>Xu J, Xu M, Hurd YL, Pasternak GW, Pan YX: Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. J Neurochem. 2009 Feb;108(4):962-72. Epub 2008 Dec 10.</reference_text>
      <pubmed_id>19077058</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6.  Nature. 2003 Oct 23;425(6960):805-11.</reference_text>
      <pubmed_id>14574404</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Uhl GR, Sora I, Wang Z: The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7752-5.</reference_text>
      <pubmed_id>10393893</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chuang TK, Killam KF Jr, Chuang LF, Kung HF, Sheng WS, Chao CC, Yu L, Chuang RY: Mu opioid receptor gene expression in immune cells.  Biochem Biophys Res Commun. 1995 Nov 22;216(3):922-30.</reference_text>
      <pubmed_id>7488213</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ancevska-Taneva N, Onoprishvili I, Andria ML, Hiller JM, Simon EJ: A member of the heat shock protein 40 family, hlj1, binds to the carboxyl tail of the human mu opioid receptor. Brain Res. 2006 Apr 7;1081(1):28-33. Epub 2006 Mar 20.</reference_text>
      <pubmed_id>16542645</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D: Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry. 1997 Oct-Nov;2(6):490-4.</reference_text>
      <pubmed_id>9399694</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L: Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9608-13.</reference_text>
      <pubmed_id>9689128</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Grond S, Sablotzki A: Clinical pharmacology of tramadol.  Clin Pharmacokinet. 2004;43(13):879-923.</reference_text>
        <pubmed_id>15509185</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Takahama K, Shirasaki T: Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs. Cough. 2007 Jul 9;3:8.</reference_text>
        <pubmed_id>17620111</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Freissmuth M, Beindl W, Kratzel M: Binding and structure-activity-relation of benzo[f]isoquinoline- and norcodeinone-derivatives at mu-opioid receptors in the rat cerebral cortex. Br J Pharmacol. 1993 Dec;110(4):1429-36.</reference_text>
        <pubmed_id>8306082</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Gillen C, Haurand M, Kobelt DJ, Wnendt S: Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):116-21.</reference_text>
        <pubmed_id>10961373</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Potschka H, Friderichs E, Loscher W: Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000 Sep;131(2):203-12.</reference_text>
        <pubmed_id>10991912</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992 Jan;260(1):275-85.</reference_text>
        <pubmed_id>1309873</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Grond S, Sablotzki A: Clinical pharmacology of tramadol.  Clin Pharmacokinet. 2004;43(13):879-923.</reference_text>
        <pubmed_id>15509185</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K: Mu opioid receptor-dependent and independent components in effects of tramadol.  Neuropharmacology. 2006 Sep;51(3):651-8. Epub 2006 Jun 21.</reference_text>
        <pubmed_id>16793069</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Minami K, Uezono Y, Ueta Y: Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci. 2007 Mar;103(3):253-60.</reference_text>
        <pubmed_id>17380034</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain.  Arzneimittelforschung. 1996 Nov;46(11):1029-36.</reference_text>
        <pubmed_id>8955860</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10.</reference_text>
        <pubmed_id>16530171</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Choi HS, Kim CS, Hwang CK, Song KY, Wang W, Qiu Y, Law PY, Wei LN, Loh HH: The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun. 2006 May 19;343(4):1132-40. Epub 2006 Mar 23.</reference_text>
        <pubmed_id>16580639</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Castro RR, Cunha FQ, Silva FS Jr, Rocha FA: A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide. Osteoarthritis Cartilage. 2006 Aug;14(8):769-76. Epub 2006 Mar 31.</reference_text>
        <pubmed_id>16580848</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, Henderson G: Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol. 2006 Aug;70(2):676-85. Epub 2006 May 8.</reference_text>
        <pubmed_id>16682505</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G: Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002 Apr;19(4):459-60.</reference_text>
        <pubmed_id>11933204</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Kakko J, von Wachenfeldt J, Svanborg KD, Lidstrom J, Barr CS, Heilig M: Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Biol Psychiatry. 2008 Jan 15;63(2):172-7. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17850768</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Kvam TM, Baar C, Rakvag TT, Kaasa S, Krokan HE, Skorpen F: Genetic analysis of the murine mu opioid receptor: increased complexity of Oprm gene splicing. J Mol Med (Berl). 2004 Apr;82(4):250-5. Epub 2004 Jan 9.</reference_text>
        <pubmed_id>14991152</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxycodone</name>
        <accession>HMDB14640</accession>
      </metabolite>
      <reference>
        <reference_text>Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review.  Clin Transl Oncol. 2007 May;9(5):298-307.</reference_text>
        <pubmed_id>17525040</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxycodone</name>
        <accession>HMDB14640</accession>
      </metabolite>
      <reference>
        <reference_text>Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain.  Curr Med Res Opin. 2008 Jan;24(1):175-92.</reference_text>
        <pubmed_id>18039433</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxycodone</name>
        <accession>HMDB14640</accession>
      </metabolite>
      <reference>
        <reference_text>Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. Epub 2009 May 27.</reference_text>
        <pubmed_id>19474215</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levallorphan</name>
        <accession>HMDB14647</accession>
      </metabolite>
      <reference>
        <reference_text>Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41.</reference_text>
        <pubmed_id>8968334</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levallorphan</name>
        <accession>HMDB14647</accession>
      </metabolite>
      <reference>
        <reference_text>Traynor JR, Nahorski SR: Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1995 Apr;47(4):848-54.</reference_text>
        <pubmed_id>7723747</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levallorphan</name>
        <accession>HMDB14647</accession>
      </metabolite>
      <reference>
        <reference_text>Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR: mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol. 1997 Jan;51(1):87-96.</reference_text>
        <pubmed_id>9016350</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levallorphan</name>
        <accession>HMDB14647</accession>
      </metabolite>
      <reference>
        <reference_text>Emmerson PJ, Clark MJ, Mansour A, Akil H, Woods JH, Medzihradsky F: Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther. 1996 Sep;278(3):1121-7.</reference_text>
        <pubmed_id>8819494</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levallorphan</name>
        <accession>HMDB14647</accession>
      </metabolite>
      <reference>
        <reference_text>Morgan D, Picker MJ: The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor. Psychopharmacology (Berl). 1998 Nov;140(1):20-8.</reference_text>
        <pubmed_id>9862398</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Vivian JA, DeYoung MB, Sumpter TL, Traynor JR, Lewis JW, Woods JH: kappa-Opioid receptor effects of butorphanol in rhesus monkeys.  J Pharmacol Exp Ther. 1999 Jul;290(1):259-65.</reference_text>
        <pubmed_id>10381785</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60.</reference_text>
        <pubmed_id>12127012</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90.</reference_text>
        <pubmed_id>12470863</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8.</reference_text>
        <pubmed_id>15942128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41.</reference_text>
        <pubmed_id>8968334</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85.</reference_text>
        <pubmed_id>8746803</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17.</reference_text>
        <pubmed_id>9399970</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50.</reference_text>
        <pubmed_id>7705457</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2.</reference_text>
        <pubmed_id>17909753</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propoxyphene</name>
        <accession>HMDB14785</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propoxyphene</name>
        <accession>HMDB14785</accession>
      </metabolite>
      <reference>
        <reference_text>Ulens C, Daenens P, Tytgat J: Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78.</reference_text>
        <pubmed_id>10690289</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propoxyphene</name>
        <accession>HMDB14785</accession>
      </metabolite>
      <reference>
        <reference_text>Tyers MB: A classification of opiate receptors that mediate antinociception in animals.  Br J Pharmacol. 1980 Jul;69(3):503-12.</reference_text>
        <pubmed_id>6249436</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propoxyphene</name>
        <accession>HMDB14785</accession>
      </metabolite>
      <reference>
        <reference_text>Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17.</reference_text>
        <pubmed_id>9399970</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propoxyphene</name>
        <accession>HMDB14785</accession>
      </metabolite>
      <reference>
        <reference_text>Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70.</reference_text>
        <pubmed_id>7562497</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propoxyphene</name>
        <accession>HMDB14785</accession>
      </metabolite>
      <reference>
        <reference_text>Bannwarth B, Richez C: The dextropropoxyphene controversy.  Joint Bone Spine. 2009 Oct;76(5):449-51. Epub 2009 Jul 14.</reference_text>
        <pubmed_id>19604717</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propoxyphene</name>
        <accession>HMDB14785</accession>
      </metabolite>
      <reference>
        <reference_text>Walker EA, Tiano MJ, Benyas SI, Dykstra LA, Picker MJ: Naltrexone and beta-funaltrexamine antagonism of the antinociceptive and response rate-decreasing effects of morphine, dezocine, and d-propoxyphene. Psychopharmacology (Berl). 1999 May;144(1):45-53.</reference_text>
        <pubmed_id>10379623</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentazocine</name>
        <accession>HMDB14790</accession>
      </metabolite>
      <reference>
        <reference_text>Levine JD, Gordon NC: Synergism between the analgesic actions of morphine and pentazocine.  Pain. 1988 Jun;33(3):369-72.</reference_text>
        <pubmed_id>3419842</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentazocine</name>
        <accession>HMDB14790</accession>
      </metabolite>
      <reference>
        <reference_text>Martin BR, Katzen JS, Woods JA, Tripathi HL, Harris LS, May EL: Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain. J Pharmacol Exp Ther. 1984 Dec;231(3):539-44.</reference_text>
        <pubmed_id>6094791</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentazocine</name>
        <accession>HMDB14790</accession>
      </metabolite>
      <reference>
        <reference_text>Kamei J, Iwamoto Y, Misawa M, Nagase H, Kasuya Y: Effects of diabetes on the antinociceptive effect of (+/-)pentazocine in mice.  Res Commun Chem Pathol Pharmacol. 1994 Apr;84(1):105-10.</reference_text>
        <pubmed_id>8042002</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentazocine</name>
        <accession>HMDB14790</accession>
      </metabolite>
      <reference>
        <reference_text>Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41.</reference_text>
        <pubmed_id>8968334</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentazocine</name>
        <accession>HMDB14790</accession>
      </metabolite>
      <reference>
        <reference_text>Saha N, Datta H, Sharma PL: Effects of morphine, buprenorphine, pentazocine and nalorphine on acquisition and extinction of active avoidance responses in rats. Indian J Physiol Pharmacol. 1990 Jul;34(3):179-82.</reference_text>
        <pubmed_id>2286420</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Kato H: [Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence]. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2008 Oct;43(5):697-704.</reference_text>
        <pubmed_id>19068776</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35.</reference_text>
        <pubmed_id>18354714</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Goodman AJ, Le Bourdonnec B, Dolle RE: Mu opioid receptor antagonists: recent developments.  ChemMedChem. 2007 Nov;2(11):1552-70.</reference_text>
        <pubmed_id>17918759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Barrios de Tomasi E, Juarez-Gonzalez J: [Opioid antagonists and alcohol consumption].  Rev Neurol. 2007 Aug 1-15;45(3):155-62.</reference_text>
        <pubmed_id>17661275</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, McCaul ME: Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008 Feb;33(3):653-65. Epub 2007 May 9.</reference_text>
        <pubmed_id>17487229</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Herz A: Opioid reward mechanisms: a key role in drug abuse?  Can J Physiol Pharmacol. 1998 Mar;76(3):252-8.</reference_text>
        <pubmed_id>9673788</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sufentanil</name>
        <accession>HMDB14846</accession>
      </metabolite>
      <reference>
        <reference_text>Hurle MA: Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem. 2001 Apr;77(2):486-92.</reference_text>
        <pubmed_id>11299311</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sufentanil</name>
        <accession>HMDB14846</accession>
      </metabolite>
      <reference>
        <reference_text>Levron JC: [Pharmacokinetics and pharmacodynamics of morphinomimetics in the central nervous system]. Agressologie. 1991;32(6-7):318-20.</reference_text>
        <pubmed_id>1688220</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sufentanil</name>
        <accession>HMDB14846</accession>
      </metabolite>
      <reference>
        <reference_text>Ilien B, Galzi JL, Mejean A, Goeldner M, Hirth C: A mu-opioid receptor-filter assay. Rapid estimation of binding affinity of ligands and reversibility of long-lasting ligand-receptor complexes. Biochem Pharmacol. 1988 Oct 15;37(20):3843-51.</reference_text>
        <pubmed_id>2847746</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sufentanil</name>
        <accession>HMDB14846</accession>
      </metabolite>
      <reference>
        <reference_text>Colpaert FC, Leysen JE, Michiels M, van den Hoogen RH: Epidural and intravenous sufentanil in the rat: analgesia, opiate receptor binding, and drug concentrations in plasma and brain. Anesthesiology. 1986 Jul;65(1):41-9.</reference_text>
        <pubmed_id>3014923</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sufentanil</name>
        <accession>HMDB14846</accession>
      </metabolite>
      <reference>
        <reference_text>Leysen JE, Gommeren W: In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor. Arch Int Pharmacodyn Ther. 1982 Dec;260(2):287-9.</reference_text>
        <pubmed_id>6131653</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sufentanil</name>
        <accession>HMDB14846</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfentanil</name>
        <accession>HMDB14940</accession>
      </metabolite>
      <reference>
        <reference_text>Garrido M, Gubbens-Stibbe J, Tukker E, Cox E, von Frijtag J, Kunzel D, IJzerman A, Danhof M, van der Graaf PH: Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor "knockdown" in vivo. Pharm Res. 2000 Jun;17(6):653-9.</reference_text>
        <pubmed_id>10955836</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfentanil</name>
        <accession>HMDB14940</accession>
      </metabolite>
      <reference>
        <reference_text>Lotsch J, Geisslinger G: Are mu-opioid receptor polymorphisms important for clinical opioid therapy?  Trends Mol Med. 2005 Feb;11(2):82-9.</reference_text>
        <pubmed_id>15694871</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfentanil</name>
        <accession>HMDB14940</accession>
      </metabolite>
      <reference>
        <reference_text>Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J: The mu-opioid receptor gene polymorphism 118A&gt;G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics. 2006 Sep;16(9):625-36.</reference_text>
        <pubmed_id>16906017</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfentanil</name>
        <accession>HMDB14940</accession>
      </metabolite>
      <reference>
        <reference_text>Leung A, Wallace MS, Ridgeway B, Yaksh T: Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.</reference_text>
        <pubmed_id>11240090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfentanil</name>
        <accession>HMDB14940</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83.</reference_text>
        <pubmed_id>15589524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823.</reference_text>
        <pubmed_id>16114980</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia.  CNS Drugs. 2005;19(12):1069-74.</reference_text>
        <pubmed_id>16332149</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Dosen-Micovic L, Ivanovic M, Micovic V: Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor. Bioorg Med Chem. 2006 May 1;14(9):2887-95. Epub 2006 Jan 11.</reference_text>
        <pubmed_id>16376082</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Dardonville C, Fernandez-Fernandez C, Gibbons SL, Ryan GJ, Jagerovic N, Gabilondo AM, Meana JJ, Callado LF: Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. Bioorg Med Chem. 2006 Oct 1;14(19):6570-80. Epub 2006 Jun 23.</reference_text>
        <pubmed_id>16797997</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. Epub 2009 Apr 29.</reference_text>
        <pubmed_id>19403616</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Kishioka S, Ko MC, Woods JH: Diltiazem enhances the analgesic but not the respiratory depressant effects of morphine in rhesus monkeys. Eur J Pharmacol. 2000 May 26;397(1):85-92.</reference_text>
        <pubmed_id>10844102</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Hoehe M, Duka T: Opiates increase plasma catecholamines in humans.  Psychoneuroendocrinology. 1993;18(2):141-8.</reference_text>
        <pubmed_id>8388112</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Zernig G, Lewis JW, Woods JH: Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception. Psychopharmacology (Berl). 1997 Feb;129(3):233-42.</reference_text>
        <pubmed_id>9084061</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17.</reference_text>
        <pubmed_id>9399970</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>McNicol ED, Boyce D, Schumann R, Carr DB: Mu-opioid antagonists for opioid-induced bowel dysfunction.  Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006332.</reference_text>
        <pubmed_id>18425947</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Tao PL, Liang KW, Sung WY, Wu YT, Huang EY: Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats. Drug Alcohol Depend. 2006 Sep 15;84(2):175-81. Epub 2006 Mar 6.</reference_text>
        <pubmed_id>16517095</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Smith MA, Greene-Naples JL, Lyle MA, Iordanou JC, Felder JN: The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors. J Pharmacol Exp Ther. 2009 Aug;330(2):468-75. Epub 2009 Apr 29.</reference_text>
        <pubmed_id>19403853</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Mello NK, Mendelson JH, Sholar MB, Jaszyna-Gasior M, Goletiani N, Siegel AJ: Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology. 2005 Mar;30(3):618-32.</reference_text>
        <pubmed_id>15602503</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Meerpohl JJ, Timmer A: [News from the cochrane library: mu opioid antagonists for opioid-induced bowel dysfunction]. Z Gastroenterol. 2008 Sep;46(9):917-21. Epub 2008 Sep 22.</reference_text>
        <pubmed_id>18810678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Peng X, Knapp BI, Bidlack JM, Neumeyer JL: Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem. 2007 May 3;50(9):2254-8. Epub 2007 Apr 4.</reference_text>
        <pubmed_id>17407276</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levorphanol</name>
        <accession>HMDB14992</accession>
      </metabolite>
      <reference>
        <reference_text>Allen RM, Granger AL, Dykstra LA: The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov;307(2):785-92. Epub 2003 Sep 15.</reference_text>
        <pubmed_id>12975489</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levorphanol</name>
        <accession>HMDB14992</accession>
      </metabolite>
      <reference>
        <reference_text>Prommer E: Levorphanol: the forgotten opioid.  Support Care Cancer. 2007 Mar;15(3):259-64. Epub 2006 Oct 13.</reference_text>
        <pubmed_id>17039381</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823.</reference_text>
        <pubmed_id>16114980</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia.  CNS Drugs. 2005;19(12):1069-74.</reference_text>
        <pubmed_id>16332149</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Warner DS, Hindman BJ, Todd MM, Sawin PD, Kirchner J, Roland CL, Jamerson BD: Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Anesth Analg. 1996 Aug;83(2):348-53.</reference_text>
        <pubmed_id>8694317</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Guy J, Hindman BJ, Baker KZ, Borel CO, Maktabi M, Ostapkovich N, Kirchner J, Todd MM, Fogarty-Mack P, Yancy V, Sokoll MD, McAllister A, Roland C, Young WL, Warner DS: Comparison of remifentanil and fentanyl in patients undergoing craniotomy for supratentorial space-occupying lesions. Anesthesiology. 1997 Mar;86(3):514-24.</reference_text>
        <pubmed_id>9066316</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Hoke JF, Cunningham F, James MK, Muir KT, Hoffman WE: Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther. 1997 Apr;281(1):226-32.</reference_text>
        <pubmed_id>9103501</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Patel SS, Spencer CM: Remifentanil.  Drugs. 1996 Sep;52(3):417-27; discussion 428.</reference_text>
        <pubmed_id>8875131</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anileridine</name>
        <accession>HMDB15049</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anileridine</name>
        <accession>HMDB15049</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anileridine</name>
        <accession>HMDB15049</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC: The antitussive activity of delta-opioid receptor stimulation in guinea pigs.  J Pharmacol Exp Ther. 2000 Feb;292(2):803-9.</reference_text>
        <pubmed_id>10640321</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16.</reference_text>
        <pubmed_id>16291875</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80.</reference_text>
        <pubmed_id>2849950</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4.</reference_text>
        <pubmed_id>14600248</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL: Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010 Oct;212(2):193-203. Epub 2010 Jul 28.</reference_text>
        <pubmed_id>20665209</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr: The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. Epub 2008 Jul 7.</reference_text>
        <pubmed_id>18606504</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenoxylate</name>
        <accession>HMDB15213</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenoxylate</name>
        <accession>HMDB15213</accession>
      </metabolite>
      <reference>
        <reference_text>Baker DE: Loperamide: a pharmacological review.  Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.</reference_text>
        <pubmed_id>18192961</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenoxylate</name>
        <accession>HMDB15213</accession>
      </metabolite>
      <reference>
        <reference_text>Corazziari E: Role of opioid ligands in the irritable bowel syndrome.  Can J Gastroenterol. 1999 Mar;13 Suppl A:71A-75A.</reference_text>
        <pubmed_id>10202212</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenoxylate</name>
        <accession>HMDB15213</accession>
      </metabolite>
      <reference>
        <reference_text>Coupar IM: The peristaltic reflex in the rat ileum: evidence for functional mu- and delta-opiate receptors. J Pharm Pharmacol. 1995 Aug;47(8):643-6.</reference_text>
        <pubmed_id>8583364</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenoxylate</name>
        <accession>HMDB15213</accession>
      </metabolite>
      <reference>
        <reference_text>De Luca A, Coupar IM: Difenoxin and loperamide: studies on possible mechanisms of intestinal antisecretory action. Naunyn Schmiedebergs Arch Pharmacol. 1993 Feb;347(2):231-7.</reference_text>
        <pubmed_id>8386327</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Narita M, Suzuki M, Mizoguchi H, Narita M, Yajima Y, Sakurada S, Tseng LF, Suzuki T: Up-regulation of mu-opioid receptor-mediated G-protein activation in protein kinase Cgamma knockout mice following repeated naloxone treatment. Neurosci Lett. 2003 Feb 27;338(2):103-6.</reference_text>
        <pubmed_id>12566163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Freye E, Latasch L, Von Bredow G, Neruda B: [The opioid tramadol demonstrates excitatory properties of non-opioid character--a preclinical study using alfentanil as a comparison]. Schmerz. 1998 Feb 28;12(1):19-24.</reference_text>
        <pubmed_id>12799988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Neal CR Jr, Owens CE, Taylor LP, Hoversten MT, Akil H, Watson SJ Jr: Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors. J Chem Neuroanat. 2003 Jul;25(4):233-47.</reference_text>
        <pubmed_id>12842269</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Spetea M, Toth F, Schutz J, Otvos F, Toth G, Benyhe S, Borsodi A, Schmidhammer H: Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist. Eur J Neurosci. 2003 Jul;18(2):290-5.</reference_text>
        <pubmed_id>12887410</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Marek GJ: Behavioral evidence for mu-opioid and 5-HT2A receptor interactions.  Eur J Pharmacol. 2003 Aug 1;474(1):77-83.</reference_text>
        <pubmed_id>12909198</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35.</reference_text>
        <pubmed_id>18354714</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Goodman AJ, Le Bourdonnec B, Dolle RE: Mu opioid receptor antagonists: recent developments.  ChemMedChem. 2007 Nov;2(11):1552-70.</reference_text>
        <pubmed_id>17918759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>van Dorp EL, Yassen A, Dahan A: Naloxone treatment in opioid addiction: the risks and benefits.  Expert Opin Drug Saf. 2007 Mar;6(2):125-32.</reference_text>
        <pubmed_id>17367258</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Spetea M, Nevin ST, Hosztafi S, Ronai AZ, Toth G, Borsodi A: Affinity profiles of novel delta-receptor selective benzofuran derivatives of non-peptide opioids. Neurochem Res. 1998 Sep;23(9):1211-6.</reference_text>
        <pubmed_id>9712193</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, Kalso EA: Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology. 2006 Oct;105(4):801-12.</reference_text>
        <pubmed_id>17006080</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Chamberlin KW, Cottle M, Neville R, Tan J: Oral oxymorphone for pain management.  Ann Pharmacother. 2007 Jul;41(7):1144-52. Epub 2007 Jun 26.</reference_text>
        <pubmed_id>17595308</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Halimi G, Devaux C, Clot-Faybesse O, Sampol J, Legof L, Rochat H, Guieu R: Modulation of adenosine concentration by opioid receptor agonists in rat striatum. Eur J Pharmacol. 2000 Jun 16;398(2):217-24.</reference_text>
        <pubmed_id>10854833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Gardell LR, King T, Ossipov MH, Rice KC, Lai J, Vanderah TW, Porreca F: Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett. 2006 Mar 20;396(1):44-9. Epub 2005 Dec 15.</reference_text>
        <pubmed_id>16343768</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dezocine</name>
        <accession>HMDB15340</accession>
      </metabolite>
      <reference>
        <reference_text>Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17.</reference_text>
        <pubmed_id>9399970</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dezocine</name>
        <accession>HMDB15340</accession>
      </metabolite>
      <reference>
        <reference_text>Barrett AC, Cook CD, Terner JM, Craft RM, Picker MJ: Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids. Psychopharmacology (Berl). 2001 Nov;158(2):154-64.</reference_text>
        <pubmed_id>11702089</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dezocine</name>
        <accession>HMDB15340</accession>
      </metabolite>
      <reference>
        <reference_text>Cook CD, Barrett AC, Roach EL, Bowman JR, Picker MJ: Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor. Psychopharmacology (Berl). 2000 Jul;150(4):430-42.</reference_text>
        <pubmed_id>10958085</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dezocine</name>
        <accession>HMDB15340</accession>
      </metabolite>
      <reference>
        <reference_text>Gharagozlou P, Demirci H, David Clark J, Lameh J: Activity of opioid ligands in cells expressing cloned mu opioid receptors.  BMC Pharmacol. 2003 Jan 4;3:1. Epub 2003 Jan 4.</reference_text>
        <pubmed_id>12513698</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dezocine</name>
        <accession>HMDB15340</accession>
      </metabolite>
      <reference>
        <reference_text>Morgan D, Cook CD, Smith MA, Picker MJ: An examination of the interactions between the antinociceptive effects of morphine and various mu-opioids: the role of intrinsic efficacy and stimulus intensity. Anesth Analg. 1999 Feb;88(2):407-13.</reference_text>
        <pubmed_id>9972766</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dezocine</name>
        <accession>HMDB15340</accession>
      </metabolite>
      <reference>
        <reference_text>Jacobs AM, Youngblood F: Opioid receptor affinity for agonist-antagonist analgesics.  J Am Podiatr Med Assoc. 1992 Oct;82(10):520-4.</reference_text>
        <pubmed_id>1361946</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levomethadyl Acetate</name>
        <accession>HMDB15358</accession>
      </metabolite>
      <reference>
        <reference_text>Yu Y, Zhang L, Yin X, Sun H, Uhl GR, Wang JB: Mu opioid receptor phosphorylation, desensitization, and ligand efficacy.  J Biol Chem. 1997 Nov 14;272(46):28869-74.</reference_text>
        <pubmed_id>9360954</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levomethadyl Acetate</name>
        <accession>HMDB15358</accession>
      </metabolite>
      <reference>
        <reference_text>Skoulis NP, James RC, Harbison RD, Roberts SM: Depression of hepatic glutathione by opioid analgesic drugs in mice.  Toxicol Appl Pharmacol. 1989 Jun 1;99(1):139-47.</reference_text>
        <pubmed_id>2471291</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levomethadyl Acetate</name>
        <accession>HMDB15358</accession>
      </metabolite>
      <reference>
        <reference_text>Kreek MJ: Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.</reference_text>
        <pubmed_id>10911931</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levomethadyl Acetate</name>
        <accession>HMDB15358</accession>
      </metabolite>
      <reference>
        <reference_text>Xiao Y, Smith RD, Caruso FS, Kellar KJ: Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther. 2001 Oct;299(1):366-71.</reference_text>
        <pubmed_id>11561100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levomethadyl Acetate</name>
        <accession>HMDB15358</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadyl Acetate</name>
        <accession>HMDB15502</accession>
      </metabolite>
      <reference>
        <reference_text>Mancino MJ, McGaugh J, Feldman Z, Poling J, Oliveto A: Effect of PTSD diagnosis and contingency management procedures on cocaine use in dually cocaine- and opioid-dependent individuals maintained on LAAM: a retrospective analysis. Am J Addict. 2010 Mar-Apr;19(2):169-77.</reference_text>
        <pubmed_id>20163389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadyl Acetate</name>
        <accession>HMDB15502</accession>
      </metabolite>
      <reference>
        <reference_text>Walczak SA, Makman MH, Gardner EL: Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9.</reference_text>
        <pubmed_id>6268422</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadyl Acetate</name>
        <accession>HMDB15502</accession>
      </metabolite>
      <reference>
        <reference_text>Wolstein J, Gastpar M, Finkbeiner T, Heinrich C, Heitkamp R, Poehlke T, Scherbaum N: A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry. 2009 Jan;42(1):1-8. Epub 2009 Jan 19.</reference_text>
        <pubmed_id>19153939</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadyl Acetate</name>
        <accession>HMDB15502</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethylmorphine</name>
        <accession>HMDB15509</accession>
      </metabolite>
      <reference>
        <reference_text>Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10.</reference_text>
        <pubmed_id>16530171</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethylmorphine</name>
        <accession>HMDB15509</accession>
      </metabolite>
      <reference>
        <reference_text>Choi HS, Kim CS, Hwang CK, Song KY, Wang W, Qiu Y, Law PY, Wei LN, Loh HH: The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun. 2006 May 19;343(4):1132-40. Epub 2006 Mar 23.</reference_text>
        <pubmed_id>16580639</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethylmorphine</name>
        <accession>HMDB15509</accession>
      </metabolite>
      <reference>
        <reference_text>Castro RR, Cunha FQ, Silva FS Jr, Rocha FA: A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide. Osteoarthritis Cartilage. 2006 Aug;14(8):769-76. Epub 2006 Mar 31.</reference_text>
        <pubmed_id>16580848</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethylmorphine</name>
        <accession>HMDB15509</accession>
      </metabolite>
      <reference>
        <reference_text>Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, Henderson G: Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol. 2006 Aug;70(2):676-85. Epub 2006 May 8.</reference_text>
        <pubmed_id>16682505</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethylmorphine</name>
        <accession>HMDB15509</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alvimopan</name>
        <accession>HMDB15631</accession>
      </metabolite>
      <reference>
        <reference_text>Kraft MD: Emerging pharmacologic options for treating postoperative ileus.  Am J Health Syst Pharm. 2007 Oct 15;64(20 Suppl 13):S13-20.</reference_text>
        <pubmed_id>17909271</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alvimopan</name>
        <accession>HMDB15631</accession>
      </metabolite>
      <reference>
        <reference_text>[No authors listed]</reference_text>
        <pubmed_id>18373729</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alvimopan</name>
        <accession>HMDB15631</accession>
      </metabolite>
      <reference>
        <reference_text>Saufl NM, Strzyzewski N: Nurses are everywhere: a practical perspective on the surgical team in managing postoperative ileus. J Perianesth Nurs. 2006 Apr;21(2A Suppl):S24-9.</reference_text>
        <pubmed_id>16597533</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alvimopan</name>
        <accession>HMDB15631</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alvimopan</name>
        <accession>HMDB15631</accession>
      </metabolite>
      <reference>
        <reference_text>Neary P, Delaney CP: Alvimopan.  Expert Opin Investig Drugs. 2005 Apr;14(4):479-88.</reference_text>
        <pubmed_id>15882122</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alvimopan</name>
        <accession>HMDB15631</accession>
      </metabolite>
      <reference>
        <reference_text>Schmidt WK: Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.  Am J Surg. 2001 Nov;182(5A Suppl):27S-38S.</reference_text>
        <pubmed_id>11755894</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
